Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Endocrinology
•
Thyroid Disorders
How often and in what way do you monitor patients who are receiving teprotumumab (Tepezza) for thyroid eye disease?
Related Questions
How should patients time the ingestion of their alendronate and levothyroxine given issues with food/drug interactions?
In patients with differentiated thyroid cancer, do you consider pathology characteristics not found in the ATA risk stratification guidelines (ie microscopic margins or multifocal cancer) when determining recurrence risk and management?
How often do you refer patients with hypothyroidism and Type D personality traits, characterized by worry and pessimism, to psychiatry after prescribing standard hypothyroidism treatment?
Is there a role for levothyroxine in managing the symptoms of a patient with euthyroid Hashimoto’s thyroiditis?
Which brand/preparation of levothyroxine do you recommend to treat hypothyroid patients with alpha-gal allergy?
Do SSRIs affect the absorption of Levothyroxine therapy when taken concomitantly?
How do you counsel a patient with hypothyroidism who complains of persistent hypothyroid symptoms despite achieving normal TSH values with levothyroxine?
How do you choose between antithyroid drugs, RAI, and surgery for hyperthyroidism patients with existing cardiovascular disease, given their varying effects on cardiovascular outcomes?
What factors would lead you to extend the duration of antithyroid drug therapy in a patient with Graves' disease who is clinically euthyroid at 12 months but has risk factors for recurrence?
How does papillary thyroid carcinoma with tall cell features (PTC TCF) compare to tall cell variant papillary thyroid carcinoma (TCV PTC) with regards to their clinicohistopathological features and risk of recurrence?
